PL3242947T3 - Terapia genowa i elektroporacja do leczenia zmian złośliwych - Google Patents

Terapia genowa i elektroporacja do leczenia zmian złośliwych

Info

Publication number
PL3242947T3
PL3242947T3 PL16735524T PL16735524T PL3242947T3 PL 3242947 T3 PL3242947 T3 PL 3242947T3 PL 16735524 T PL16735524 T PL 16735524T PL 16735524 T PL16735524 T PL 16735524T PL 3242947 T3 PL3242947 T3 PL 3242947T3
Authority
PL
Poland
Prior art keywords
malignancies
electroporation
treatment
gene therapy
therapy
Prior art date
Application number
PL16735524T
Other languages
English (en)
Polish (pl)
Inventor
Robert H. Pierce
Jocelyn H. Wright
Original Assignee
Oncosec Medical Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncosec Medical Incorporated filed Critical Oncosec Medical Incorporated
Publication of PL3242947T3 publication Critical patent/PL3242947T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL16735524T 2015-01-09 2016-01-08 Terapia genowa i elektroporacja do leczenia zmian złośliwych PL3242947T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562101850P 2015-01-09 2015-01-09
US201562126300P 2015-02-27 2015-02-27
EP16735524.7A EP3242947B1 (en) 2015-01-09 2016-01-08 Gene therapy and electroporation for the treatment of malignancies
PCT/US2016/012759 WO2016112359A1 (en) 2015-01-09 2016-01-08 Method for the treatment of malignancies

Publications (1)

Publication Number Publication Date
PL3242947T3 true PL3242947T3 (pl) 2021-01-11

Family

ID=56356515

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16735524T PL3242947T3 (pl) 2015-01-09 2016-01-08 Terapia genowa i elektroporacja do leczenia zmian złośliwych

Country Status (9)

Country Link
US (1) US20180000895A1 (enExample)
EP (2) EP3242947B1 (enExample)
JP (3) JP2018504403A (enExample)
CA (1) CA2973390A1 (enExample)
DK (1) DK3242947T3 (enExample)
ES (1) ES2809734T3 (enExample)
MX (1) MX383277B (enExample)
PL (1) PL3242947T3 (enExample)
WO (1) WO2016112359A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2809734T3 (es) * 2015-01-09 2021-03-05 Oncosec Medical Inc Terapia génica y electroporación para el tratamiento de neoplasias malignas
EP4209190A1 (en) 2016-06-27 2023-07-12 Galvanize Therapeutics, Inc. System comprising a generator and a catheter with an electrode for treating a lung passageway
US12403305B2 (en) 2016-06-27 2025-09-02 Galvanize Therapeutics, Inc. Immunostimulation in the treatment of viral infection
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP2021508533A (ja) 2017-12-26 2021-03-11 ギャラリー，インコーポレイテッド 様々な用途のためのエネルギー送達の最適化
MX2020011618A (es) * 2018-05-02 2021-02-16 Oncosec Medical Inc Sistemas, métodos y aparatos de electroporación.
KR102753455B1 (ko) * 2018-08-08 2025-01-10 세다르스-신나이 메디칼 센터 암 및 자가면역 질환을 치료하기 위한 조성물 및 방법
JP7586890B2 (ja) 2019-07-16 2024-11-19 ガルヴァナイズ セラピューティクス，インコーポレイテッド パルス電界による生殖器の治療
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
CN119213021A (zh) 2022-02-10 2024-12-27 艾菲赛尔治疗株式会社 与CD40L特异性结合的Stefin A蛋白变体及其用途
KR20250006965A (ko) 2022-04-29 2025-01-13 퓨리노미아 바이오테크, 아이엔씨. 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US20030049696A1 (en) 2001-06-07 2003-03-13 Norment Anne M. Regulatory T cells and uses thereof
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US8802643B1 (en) * 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
EA200501937A1 (ru) * 2003-05-30 2006-08-25 Университет Южной Флориды Способ лечения злокачественных опухолей
US7923251B2 (en) 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
US8101169B2 (en) 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
WO2007120368A2 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
WO2010030002A1 (ja) * 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
KR102445129B1 (ko) * 2011-12-12 2022-09-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
ES2809734T3 (es) * 2015-01-09 2021-03-05 Oncosec Medical Inc Terapia génica y electroporación para el tratamiento de neoplasias malignas

Also Published As

Publication number Publication date
EP3242947A4 (en) 2018-08-08
JP7111384B2 (ja) 2022-08-02
DK3242947T3 (da) 2020-08-03
EP3799879A1 (en) 2021-04-07
ES2809734T3 (es) 2021-03-05
JP2018504403A (ja) 2018-02-15
JP2021008481A (ja) 2021-01-28
WO2016112359A1 (en) 2016-07-14
MX383277B (es) 2025-03-13
MX2017009044A (es) 2018-01-11
EP3799879B1 (en) 2025-06-04
CA2973390A1 (en) 2016-07-14
EP3242947B1 (en) 2020-05-27
US20180000895A1 (en) 2018-01-04
JP2022137203A (ja) 2022-09-21
EP3242947A1 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
PL3242947T3 (pl) Terapia genowa i elektroporacja do leczenia zmian złośliwych
GB2604416B (en) Tumor infiltating lymphocytes and methods of therapy
IL259783A (en) Methods of treatment of malignant diseases
GB2595063B (en) Modified cells and methods of therapy
IL260959A (en) Gene therapy for the treatment of mucoid polysaccharomyces type i
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
IL256224B (en) Combined therapy for cancer treatment
IL250960B (en) Combined treatment of sinecriviroc for the treatment of leprosy
SMT201900176T1 (it) Terapia con mrna per il trattamento di malattie oculari
IL258521A (en) Combination of treatments for cancer treatment
HUE069690T2 (hu) Génterápia
IL258005A (en) Methods and materials for gene therapy for beta-4,1-en.-acetylgalactosaminyltransferase 2
HUE056570T2 (hu) Génterápia
SG10202100632WA (en) Gene therapy for the treatment of aldehyde dehydrogenase deficiency
IL256181A (en) Means and methods for treatment of b-cell malignancies
SG11201605745VA (en) Targeting clptm1l for treatment and prevention of cancer
GB201511159D0 (en) Controlled cell delivery vehicle and treatment of tumours
IL266726A (en) Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions
GB201701968D0 (en) Gene therapy
HK40006035A (en) Methods for the treatment of b cell malignancies using adoptive cell therapy
GB201416605D0 (en) Combination therapy to reduce the risk of and to treat cancer
GB201704634D0 (en) Gene therapy
GB201616821D0 (en) Gene therapy
GB201418640D0 (en) Agents and methods for treatment of cancer